BRPI0509573A - derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 - Google Patents

derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2

Info

Publication number
BRPI0509573A
BRPI0509573A BRPI0509573-5A BRPI0509573A BRPI0509573A BR PI0509573 A BRPI0509573 A BR PI0509573A BR PI0509573 A BRPI0509573 A BR PI0509573A BR PI0509573 A BRPI0509573 A BR PI0509573A
Authority
BR
Brazil
Prior art keywords
treatment
diabetes
type
thiazolpyridine
sulfonamide
Prior art date
Application number
BRPI0509573-5A
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Ramesh Chandra Gupta
Vikrant Vijaykumar Jagtap
Appaji Baburao Mandhare
Davinder Tuli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0509573A publication Critical patent/BRPI0509573A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

DERIVADOS DE SULFONAMIDA-TIAZOLPIRIDINA COMO ATIVADORES DE GLICOCINASE úTEIS PARA O TRATAMENTO DE DIABETES DO TIPO 2 . A presente invenção provê compostos da fórmula (1), que são ativadores de atividade de glicocinase e, então, podem ser empregados como agentes terapêuticas para o tratamento de condições mediadas por gilcocinase. Deste modo, os com postos da fórmula (I) podem ser empregados para a prevenção e o tratamento de tolerância à glicose prejudicada, diabetes do Tipo 2 e obesidade.
BRPI0509573-5A 2004-04-02 2005-04-01 derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 BRPI0509573A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55918404P 2004-04-02 2004-04-02
PCT/EP2005/003456 WO2005095418A1 (en) 2004-04-02 2005-04-01 Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
BRPI0509573A true BRPI0509573A (pt) 2007-09-25

Family

ID=34963913

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509573-5A BRPI0509573A (pt) 2004-04-02 2005-04-01 derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2

Country Status (19)

Country Link
US (1) US7750020B2 (pt)
EP (1) EP1735322B1 (pt)
JP (1) JP4700684B2 (pt)
KR (1) KR100830007B1 (pt)
CN (1) CN1960995B (pt)
AR (1) AR050913A1 (pt)
AT (1) ATE524479T1 (pt)
AU (1) AU2005229416B2 (pt)
BR (1) BRPI0509573A (pt)
CA (1) CA2560689C (pt)
EC (1) ECSP066894A (pt)
IL (1) IL178151A0 (pt)
MA (1) MA28528B1 (pt)
NO (1) NO20064929L (pt)
PE (1) PE20061353A1 (pt)
PT (1) PT1735322E (pt)
RU (1) RU2412192C2 (pt)
TN (1) TNSN06315A1 (pt)
WO (1) WO2005095418A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN101805358A (zh) * 2002-10-03 2010-08-18 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CN101316837A (zh) * 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的吡咯酮类
US20070117808A1 (en) * 2005-11-01 2007-05-24 Maud Urbanski Substituted Cycloalkylpyrrolones As Allosteric Modulators Of Glucokinase
CA2628259A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1960385A1 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2261216A3 (en) 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
KR20090121376A (ko) * 2007-03-07 2009-11-25 교린 세이야꾸 가부시키 가이샤 글루코키나아제 활성화 물질
WO2008119734A2 (en) * 2007-03-29 2008-10-09 Novartis Ag Process for the manufacture of organic compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
BRPI0818501A2 (pt) * 2007-10-08 2015-04-22 Advinus Therapeutics Private Ltd Derivados de acetamida como ativadores de glicoquinase, seu processo e aplicações medicinais
CN101417987B (zh) * 2007-10-24 2011-07-13 山东轩竹医药科技有限公司 具有磺酰胺甲酰哌嗪结构的dpp-iv抑制剂
RU2010134411A (ru) 2008-01-18 2012-02-27 Астеллас Фарма Инк. (Jp) Фенилацетамидное производное
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
MX2010012298A (es) 2008-05-16 2011-03-15 Takeda San Diego Inc Activadores de glucocinasa.
BRPI0918128A2 (pt) 2008-09-11 2015-11-24 Pfizer derivados de heterozril amida e seu uso como ativadores de glicocinase
RS52903B (en) 2009-03-11 2014-02-28 Pfizer Inc BENZOFURANIL DERIVATIVES FOR USE AS GLUCOKINASE INHIBITORS
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3884232B2 (ja) * 1999-03-29 2007-02-21 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化物質
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU7049401A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Alkynyl phenyl heteroaromatic glucokinase activators
EP1280801B1 (en) * 2000-05-03 2005-09-07 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
ATE398611T1 (de) * 2000-05-08 2008-07-15 Hoffmann La Roche Para-amin substituierte phenylamid glukokinase activatoren
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
KR100556323B1 (ko) 2000-07-20 2006-03-03 에프. 호프만-라 로슈 아게 알파-아실 및 알파-헤테로원자-치환된 벤젠 아세트아미드글루코키나제 활성화제
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
BR0115999A (pt) * 2000-12-06 2003-09-30 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
CZ2004747A3 (cs) 2001-12-21 2004-11-10 Novo Nordisk A/S Deriváty amidů jako GK aktivátory
WO2003080585A1 (fr) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
CA2482346C (en) 2002-04-26 2010-03-09 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
JPWO2003097824A1 (ja) 2002-05-16 2005-09-15 萬有製薬株式会社 グルコキナーゼタンパク質の結晶、及びその結晶を用いたドラッグデザイン方法
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
CN101805358A (zh) * 2002-10-03 2010-08-18 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺
MXPA05003391A (es) 2002-10-03 2005-06-22 Hoffmann La Roche Indol-3-carboxamidas como activadores de glucocinasa.
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
DK1585739T3 (da) 2003-01-06 2011-06-20 Lilly Co Eli Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1598349B1 (en) 2003-02-13 2011-07-27 Msd K.K. Novel 2-pyridinecarboxamide derivatives
JP4432901B2 (ja) 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
NZ550567A (en) 2004-04-21 2010-07-30 Prosidion Ltd Tri(cyclo) substituted amide compounds
AU2005271016A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos

Also Published As

Publication number Publication date
CN1960995B (zh) 2010-12-08
MA28528B1 (fr) 2007-04-03
KR100830007B1 (ko) 2008-05-15
TNSN06315A1 (en) 2007-12-03
ATE524479T1 (de) 2011-09-15
US7750020B2 (en) 2010-07-06
IL178151A0 (en) 2006-12-31
AU2005229416B2 (en) 2009-03-26
RU2412192C2 (ru) 2011-02-20
RU2006138433A (ru) 2008-05-10
US20080103167A1 (en) 2008-05-01
AU2005229416A1 (en) 2005-10-13
JP4700684B2 (ja) 2011-06-15
EP1735322B1 (en) 2011-09-14
KR20060131955A (ko) 2006-12-20
EP1735322A1 (en) 2006-12-27
PT1735322E (pt) 2012-01-12
CA2560689C (en) 2011-03-01
WO2005095418A1 (en) 2005-10-13
JP2007530632A (ja) 2007-11-01
CN1960995A (zh) 2007-05-09
ECSP066894A (es) 2006-11-24
NO20064929L (no) 2006-12-20
CA2560689A1 (en) 2005-10-13
PE20061353A1 (es) 2006-12-29
AR050913A1 (es) 2006-12-06

Similar Documents

Publication Publication Date Title
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
BR0314864A (pt) Compostos orgânicos
TW200745037A (en) Organic compounds
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
BR0206831A (pt) Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
GT200100183A (es) Derivados de quinolina y quinazolina.
NO20083026L (no) Terapeutisk middel for diabetes
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0514147A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
BR112012025592A2 (pt) moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
UY26130A1 (es) Compuestos para tratar la obesidad
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20072389L (no) Substituerte benzokinolizinderivater
BRPI0517947A (pt) composto de piridazina, composições e métodos
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.